ID   THJ-21T
AC   CVCL_W921
SY   THJ21T
DR   ABM; T8253
DR   cancercelllines; CVCL_W921
DR   Cosmic; 2054082
DR   Wikidata; Q54972302
RX   PubMed=20810568;
RX   PubMed=23724124;
RX   PubMed=23833040;
RX   PubMed=26680454;
RX   PubMed=30737244;
CC   Doubling time: 43 hours (PubMed=20810568).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23833040; PubMed=26680454; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11,15
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 13,15
ST   D21S11: 30
ST   D3S1358: 15,17
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 9,14
ST   FGA: 24
ST   TH01: 6
ST   TPOX: 8,12
ST   vWA: 16,17
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 10-04-25; Version: 20
//
RX   PubMed=20810568; DOI=10.1210/jc.2010-1421; PMCID=PMC2999968;
RA   Marlow L.A., D'Innocenzi J., Zhang Y.-L., Rohl S.D., Cooper S.J.,
RA   Sebo T.J., Grant C., McIver B., Kasperbauer J.L., Wadsworth J.T.,
RA   Casler J.D., Kennedy P.W., Highsmith W.E. Jr., Clark O., Milosevic D.,
RA   Netzel B.C., Cradic K.W., Arora S., Beaudry C., Grebe S.K.G.,
RA   Silverberg M.L., Azorsa D.O., Smallridge R.C., Copland J.A. 3rd;
RT   "Detailed molecular fingerprinting of four new anaplastic thyroid
RT   carcinoma cell lines and their use for verification of RhoB as a
RT   molecular therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 95:5338-5347(2010).
//
RX   PubMed=23724124; DOI=10.1371/journal.pone.0065095; PMCID=PMC3665717;
RA   Li W., Reeb A.N., Sewell W.A., Elhomsy G., Lin R.-Y.;
RT   "Phenotypic characterization of metastatic anaplastic thyroid cancer
RT   stem cells.";
RL   PLoS ONE 8:e65095.1-e65095.10(2013).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=26680454; DOI=10.1186/s12885-015-1955-9; PMCID=PMC4683857;
RA   Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J.,
RA   Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.;
RT   "The genomic and transcriptomic landscape of anaplastic thyroid
RT   cancer: implications for therapy.";
RL   BMC Cancer 15:984.1-984.11(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//